Skip to main content
Signal8

CERo Therapeutics Doses 7th Patient in Phase 1 CER-1236 Trial

$CEROPress releaseNov 3, 2026, 8:15 AM ET

CERo Therapeutics dosed the seventh patient overall, the fourth in the second cohort, of its Phase 1 CERTAIN-T trial of CER-1236 in hematologic malignancies including AML, MDS, and myelofibrosis. No dose-limiting toxicities were observed in the first three patients of the second cohort, and previously reported expansion of infused CER-1236 cells supports continued dose escalation.

Key figures

Drug Name
CER-1236
Phase Of Trial
Phase 1
Cohort
2
Patients treated
7

AI analysis

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.